Global Afamelanotide Market (2024–2032): USD 136.27M to USD 258.01M Growth at 9.1% CAGR
Global Afamelanotide Market is projected to grow from USD 136.27 million in 2024 to USD 258.01 million by 2032, registering a strong CAGR of 9.1%. Afamelanotide (SCENESSE®), the first approved treatment for EPP, enhances melanin production to improve sunlight tolerance in patients with severe phototoxic disorders. Rising awareness of rare diseases, expanding clinical trials in vitiligo and photodermatoses, and broader regulatory support are fueling market demand globally.
Global Afamelanotide Market is projected to grow from USD 136.27 million in 2024 to USD 258.01 million by 2032, registering a strong CAGR of 9.1%. Afamelanotide (SCENESSE®), the first approved treatment for EPP, enhances melanin production to improve sunlight tolerance in patients with severe phototoxic disorders. Rising awareness of rare diseases, expanding clinical trials in vitiligo and photodermatoses, and broader regulatory support are fueling market demand globally.
Global Afamelanotide Market (2024–2032): USD 136.27M to USD 258.01M Growth at 9.1% CAGR
Global Afamelanotide Market is projected to grow from USD 136.27 million in 2024 to USD 258.01 million by 2032, registering a strong CAGR of 9.1%. Afamelanotide (SCENESSE®), the first approved treatment for EPP, enhances melanin production to improve sunlight tolerance in patients with severe phototoxic disorders. Rising awareness of rare diseases, expanding clinical trials in vitiligo and photodermatoses, and broader regulatory support are fueling market demand globally.
0 Commentarios
·0 Acciones
·237 Views
·0 Vista previa